Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy

Journal of Psychiatric Research

Volumn 42, Issue 12, 2008, Pages 1000-1009

  Santen, Gijs ^a   Gomeni, Roberto ^b   Danhof, Meindert ^a   Pasqua, Oscar Della ^a,c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b GSK   (Italy)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Clinical trial design; Depression; HAMD; MRMM

Indexed keywords

PAROXETINE;

ADULT; ARTICLE; BOOTSTRAPPING; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL MODEL; TREATMENT OUTCOME;

EID: 49149092360     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2007.11.004     Document Type: Article

References (39)

1. Bagby R.M., Ryder A.G., Schuller D.R., and Marshall M.B. The Hamilton depression rating scale: has the gold standard become a lead weight?. American Journal of Psychiatry 161 (2004) 2163-2177
2. Bech P. Rating scales in depression: limitations and pitfalls. Dialogues in Clinical Neurosciences 8 (2006) 207-215
3. Bech P., and Rafaelsen O. The use of rating scales exemplified by a comparison of the Hamilton and Bech-Rafaelsen Melancholia Scale. Acta Psychiatrica Scandinavica 62 (1980) 128-131
4. Bech P., Allerup P., Gram L.F., Reisby N., Rosenberg R., Jacobsen O., et al. The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatrica Scandinavica 63 (1980) 290-299
5. Bech P., Allerup P., Reisby N., and Gram L.F. Assessment of symptom change from improvement curves on the Hamilton depression scale in trials with antidepressants. Psychopharmacology (Berl) 84 (1984) 276-281
6. Bech P., Tanghoj P., Cialdella P., Andersen H.F., and Pedersen A.G. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. International Journal of Neuropsychopharmacology 7 (2004) 283-290
7. Bech P., Engelhardt N., Evans K.R., Gibertini M., Kalali A.H., Kobak K.A., et al. Why the Hamilton depression rating scale endures. American Journal of Psychiatry 162 (2005) 2396
8. Carroll B.J. Why the Hamilton depression rating scale endures. American Journal of Psychiatry 162 (2005) 2395-2396
9. Corruble E., and Hardy P. Why the Hamilton depression rating scale endures. American Journal of Psychiatry 162 (2005) 2394
10. Culpepper L. Generalized anxiety disorder in primary care: emerging issues in management and treatment. Journal of Clinical Psychiatry 63 Suppl 8 (2002) 35-42
11. Dunner D.L., and Dunbar G.C. Optimal dose regimen for paroxetine. Journal of Clinical Psychiatry 53 Suppl (1992) 21-26
12. Evans K.R., Sills T., DeBrota D.J., Gelwicks S., Engelhardt N., and Santor D. An item response analysis of the Hamilton depression rating scale using shared data from two pharmaceutical companies. Journal of Psychiatry Research 38 (2004) 275-284
13. Faries D., Herrera J., Rayamajhi J., DeBrota D., Demitrack M., and Potter W.Z. The responsiveness of the Hamilton depression rating scale. Journal of Psychiatry Research 34 (2000) 3-10
14. Franciosi L.G., Page C.P., Celli B.R., Cazzola M., Walker M.J., Danhof M., et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics 19 (2006) 189-199
15. Golden R.N., Nemeroff C.B., McSorley P., Pitts C.D., and Dube E.M. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. Journal of Clinical Psychiatry 63 (2002) 577-584
16. Hamilton M. A rating scale for depression. Journal of Neurology Neurosurgery Psychiatry 23 (1960) 56-62
17. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social Psychology 6 (1967) 278-296
18. Healy D. Did regulators fail over selective serotonin reuptake inhibitors?. British Medical Journal 333 (2006) 92-95
19. Hsieh C.L., and Hsieh C.H. Why the Hamilton depression rating scale endures. American Journal of Psychiatry 162 (2005) 2395
20. Jonsson EN. Graphical display of population data. 2004. p. 13. Ref Type: Abstract.
21. Khan A., Warner H.A., and Brown W.A. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Archives of General Psychiatry 57 (2000) 311-317
22. Khan A., Leventhal R.M., Khan S.R., and Brown W.A. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology 22 (2002) 40-45
23. Khan A., Brodhead A.E., and Kolts R.L. Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the clinical global impressions rating scale in antidepressant clinical trials: a replication analysis. International Clinical Psychopharmacology 19 (2004) 157-160
24. Lenzer J. Manufacturer admits increase in suicidal behaviour in patients taking paroxetine. British Medical Journal 332 (2006) 1175
25. Licht R.W., and Bech P. Why the Hamilton depression rating scale endures. American Journal of Psychiatry 162 (2005) 2394-2395
26. Licht R.W., Qvitzau S., Allerup P., and Bech P. Validation of the Bech-Rafaelsen Melancholia scale and the Hamilton depression scale in patients with major depression; is the total score a valid measure of illness severity?. Acta Psychiatrica Scandinavica 111 (2005) 144-149
27. Maas H.J., Danhof M., and Della Pasqua O.E. Prediction of headache response in migraine treatment. Cephalalgia 26 (2006) 416-422
28. Maier W., and Philipp M. Comparative analysis of observer depression scales. Acta Psychiatrica Scandinavica 72 (1985) 239-245
29. Mallinckrodt C.H., Kaiser C.J., Watkin J.G., Molenberghs G., and Carroll R.J. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. Clinical Trials 1 (2004) 477-489
30. Moller H.J. Methodological aspects in the assessment of severity of depression by the Hamilton depression scale. European Archives of Psychiatry and Clinical Neuroscience 251 Suppl 2 (2001) II13-II20
31. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134 (1979) 382-389
32. Nierenberg A.A., Gray S.M., and Grandin L.D. Mood disorders and suicide. Journal of Clinical Psychiatry 62 Suppl 25 (2001) 27-30
33. O'Sullivan R.L., Fava M., Agustin C., Baer L., and Rosenbaum J.F. Sensitivity of the six-item Hamilton depression rating scale. Acta Psychiatrica Scandinavica 95 (1997) 379-384
34. Posternak M.A., and Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. Journal of Clinical Psychiatry 66 (2005) 148-158
35. R Development Core Team. R: a language and environment for statistical computing (2005), R Foundation for Statistical Computing, Vienna, Austria Ref Type Computer Program
36. Stassen H.H., and Angst J. Delayed onset of action of antidepressants: fact or fiction?. CNS Drugs 9 (1998) 177-184
37. Taylor D.J., Lichstein K.L., Durrence H.H., Reidel B.W., and Bush A.J. Epidemiology of insomnia, depression, and anxiety. Sleep 28 (2005) 1457-1464
38. Tedlow J., Fava M., Uebelacker L., Nierenberg A.A., Alpert J.E., and Rosenbaum J. Outcome definitions and predictors in depression. Psychotherapy and Psychosomatics 67 (1998) 266-270
39. Tignol J., Stoker M.J., and Dunbar G.C. Paroxetine in the treatment of melancholia and severe depression. International Clinical Psychopharmacology 7 (1992) 91-94